This 2022 lab study treated chon-001 human cartilage cells with chondroitin sulphate. The cells grew and migrated more, made more type II collagen and the enzyme brakes TIMP-1 and TIMP-2, and made less MMP-9 and MMP-2. Chondroitin also turned down signalling through Akt and NF-kB.
Researchers treated chon-001 chondrocytes, a human cartilage cell line, with chondroitin sulphate. They measured cell migration with a transwell assay; signalling proteins, TIMPs, collagen and MMPs by Western blot; MMP activity by gelatin zymography; and reactive oxygen species by fluorescence. They used a beta-catenin inhibitor and an antioxidant to test which pathways drove the changes.
Chondroitin increased cell proliferation and migration and induced an epithelial-mesenchymal transition, a change in cell shape and behaviour. It raised type II collagen, TIMP-1 and TIMP-2, and lowered the expression and activity of MMP-9 and MMP-2. Phosphorylation of Akt, IKK, IκB and p65 fell, pointing to lower NF-kB signalling. Chondroitin raised beta-catenin and reactive oxygen species. Blocking beta-catenin cut the extra growth, and an antioxidant blocked the extra migration.
This is a single cell line, not cells from people's joints, and the abstract gives no concentrations or durations. It measured MMP-9 and MMP-2, not MMP13. The authors' closing line about restoring cartilage function in patients goes well beyond what a cell line study can show.
It shows chondroitin raising TIMP-1 and TIMP-2, the cell's own MMP brakes, alongside type II collagen, the collagen MMP13 cuts. It did not test MMP13 itself, which leaves a gap in the chondroitin research on this enzyme.
The lab evidence is thin and mixed. Glucosamine lowered MMP13 in one study of human cartilage cells and stem cells, but in another it didn't change cytokine-driven...
In two main ways. Cells release MMP13 as an inactive proenzyme that must be cut before it works, and the body makes its own inhibitors, the TIMPs. TIMP-1, TIMP-2 and...